While some plans may provide coverage for certain weight-related conditions, eligibility is determined by the insurer
Maintain adequate hydration with clear to pale yellow urine as your goal, distribute fluid intake evenly throughout the day, and reduce fluids 2-3 hours before bedtime if nighttime urination disrupts sleep
Side Effects & Safety Considerations The adverse event profile of MOUNJARO (tirzepatide) is predominantly gastrointestinal, aligning with the incretin receptor agonist class, with frequency and severity correlating to dose and titration speed.[3][4] Most common reactions include nausea, diarrhea, vomiting, abdominal pain, constipation, dyspepsia, and decreased appetite.[3][4] These effects are typically mild-to-moderate, peak during dose escalation, and lessen over time on a stable dose.[3] If tolerability is significantly compromised, providers should consider delaying escalation or extending the current dose interval
It is a cognitive performance enhancer with mild antidepressant and mood-enhancing properties